Pfizer stock gains as new products lift 2026 outlook

Pfizer reported third-quarter 2026 results on Tuesday, November 3, and raised its full-year outlook after new and acquired medicines strengthened the business. In a company update, Pfizer said commercial execution and continued financial discipline supported the change.

New Products Offset COVID Declines

Third-quarter revenue totaled 16.6 billion US dollars and was broadly flat operationally from a year earlier. Excluding Comirnaty and Paxlovid, revenue increased 7 percent operationally, as sales gains from Eliquis, Padcev, the Vyndaqel family, Nurtec and Lorbrena offset lower COVID product revenue.

Launched and acquired products generated 3.8 billion US dollars in quarterly revenue and grew 32 percent operationally. Pfizer said these products, which include newer oncology, vaccine and specialty medicines, were a central contributor to the quarter's performance.

The mix shift is important for investors because Pfizer continues to move beyond the pandemic-era contribution from Comirnaty and Paxlovid. The company still expects about 4 billion US dollars of full-year COVID product revenue, with most Comirnaty sales expected during the fourth-quarter vaccination season.

Higher Guidance Raises The Bar

Pfizer lifted its 2026 revenue outlook to 62.0 billion to 64.0 billion US dollars from 60.5 billion to 62.5 billion previously. It also raised and narrowed its adjusted diluted earnings-per-share range to 2.95 to 3.05 US dollars from 2.80 to 3.00 US dollars.

Chief Executive Albert Bourla said the 32 percent operational growth in launched and acquired products showed underlying business strength. Pfizer also highlighted productivity improvements and continued investment in its pipeline, while noting that the outlook remains subject to the risks described in its filings.

Pipeline Execution Remains Key

Pfizer said it had advanced eight pivotal study starts, one pivotal readout and two regulatory decisions since its prior quarterly earnings update. Research and development spending reached 8.3 billion US dollars in the first nine months of 2026 across oncology, vaccines, inflammation and immunology, and internal medicine.

The real-time quote of Pfizer stock traded at 26.44 euros on Lang & Schwarz at 14:00 CET on Monday, November 9, 0.46 percent above the Xetra close of Friday, November 6. The move leaves the stock's near-term valuation tied to execution in newer products, the seasonal COVID contribution and progress in late-stage trials.

Pfizer trades within the broader U.S. equity market tracked by the S&P 500.

More news and analyses on Pfizer stock will remain focused on guidance delivery, pipeline milestones and the durability of growth from newer medicines.